Risk Factors Update Summary

• Anticipate significant costs related to compliance with expanded climate-related disclosures requirements.
• Changes in state laws and regulations for telehealth services could affect operations significantly.
• Revenue growth rate has declined, with revenue decreasing from 80% to 72% year-over-year.
• Revenue growth rate has declined, with a decrease from 80% to 72% in recent periods.
• Increased oversight obligations on the Board of Directors due to expanded climate-related disclosures.
• Expected benefits from restructuring efforts added, with a $1.5 million monetary settlement disclosed.
• Increased oversight obligations on management and Board may impact operations and financial results.
• The loss of large PBM partners could impact revenue, with the top 3 PBMs accounting for 32% of revenue in 2023.
• Recent restructuring efforts aim to realize benefits, including workforce reductions and cost savings.
• Recent workforce reductions and de-prioritization of solutions may lead to unintended consequences.
• Debt outstanding decreased from $667 million to $661 million under a term credit facility.
• Increased scrutiny on ESG matters may lead to higher costs and potential activism impacts.
• Potential impact on business from activism related to ESG matters, leading to increased costs.
• Historical revenue derived from prescription transactions, representing 73% of revenue in 2023.
• Reduction in workforce undertaken, affecting employees and de-prioritizing certain solutions under pharma manufacturer solutions.
• Changes in senior management roles, including the appointment of an Interim CEO, may impact business continuity.
• Changes in revenue sources, with revenue from prescription transactions representing 73%, 72%, and 80% in 2023, 2022, and 2021, respectively.
• Transition in senior management roles, with Co-CEOs transitioning and an Interim CEO appointed.
• Increased focus on AI and machine learning, with potential challenges in managing their use.
• Regulatory enforcement proceedings and inquiries may lead to litigation, settlements, or enforcement actions.